Resveratrol Effects on Metabolic Syndrome Features: A Systematic Review and Meta-Analysis

• Published in: Endocrines Vol. 5; no. 2; pp. 225 - 243
• Main Authors: Batista-Jorge, Gislaine C., Barcala-Jorge, Antônio S., Lelis, Deborah F., Santos, Daniel E., Jorge, Antônio H., Monteiro-Junior, Renato S., Santos, Sérgio H. S.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 22-05-2024
• Subjects: Adipocytes; Atherosclerosis; Blood pressure; Body fat; Body mass index; Diabetes; Disease prevention; Glucose; High density lipoprotein; Insulin; Investigations; Lifestyles; Lipids; Lipoproteins; Meta-analysis; Metabolic syndrome; Metabolites; Microbiota; Obesity; Oxidation; polyphenols; resveratrol; Systematic review; Triglycerides; Weight control
• ISSN: 2673-396X; 2673-396X
• DOI: 10.3390/endocrines5020016

Resveratrol is a natural polyphenol with important anti-inflammatory and antioxidant properties for treating cardiometabolic disorders. Therefore, the present meta-analysis aimed to review and investigate the oral resveratrol supplementation effects on metabolic syndrome (MetS) components. The bibliographic search was carried out in 2023 in the following databases: PubMed, Web of Science, and Scopus. Studies that investigated the oral resveratrol effects on the MetS parameters were included. Statistical analyses were performed using RevMan Software V.5.3. The main findings showed that resveratrol significantly decreased systolic and diastolic blood pressure while having no significant effects on waist circumference and high-density lipoprotein levels. In addition, glucose level was significantly decreased in the subgroup of studies reporting change from baseline means, although the overall effect was not statistically significant (p = 0.81), while triglyceride levels were increased after the treatment period. In conclusion, the present meta-analysis evidenced the potential therapeutic effect of resveratrol on improving some MetS features, especially regarding systolic blood pressure, diastolic blood pressure, and glucose reduction; however, the results are still borderline and sometimes controversial, which might be justified by the methodological and statistical heterogeneity of the studies, with the latter varying from 17 to 57%.